-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRP-2945 in Absence Seizure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRP-2945 in Absence Seizure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NRP-2945 in Absence Seizure Drug Details: NRP-2945 (NNZ-4945) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRP-2945 in Epileptic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRP-2945 in Epileptic Encephalopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NRP-2945 in Epileptic Encephalopathy Drug Details: NRP-2945 (NNZ-4945) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vx-001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vx-001 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vx-001 in Non-Small Cell Lung Cancer Drug Details: Vx-001 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRP-2945 in Lennox-Gastaut Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRP-2945 in Lennox-Gastaut Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NRP-2945 in Lennox-Gastaut Syndrome Drug Details: NRP-2945 (NNZ-4945) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NVCoV-2 in Respiratory Syncytial Virus (RSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NVCoV-2 in Respiratory Syncytial Virus (RSV) Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NVCoV-2 in Respiratory Syncytial Virus (RSV) Infections Drug...
-
Product Insights
Courseulles sur Mer Offshore
Courseulles sur Mer Offshore is an offshore wind project located in English Channel, France. The project is owned by Canada Pension Plan Investment Board; EDF Renewables SA; Enbridge Inc; WPD Offshore France SAS and is developed by Eolien Maritime France; WPD Offshore France SAS. The project is currently under construction. Empower your strategies with our Courseulles sur Mer Offshore report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ningetinib Toluenesulfonate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ningetinib Toluenesulfonate in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ningetinib Toluenesulfonate in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SurVaxM in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SurVaxM in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SurVaxM in Multiple Myeloma (Kahler Disease) Drug Details: SurVaxM is...
-
New
Likelihood of Approval and Phase Transition Success Rate Model – Zanzalintinib Fumarate in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanzalintinib Fumarate in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanzalintinib Fumarate in Metastatic Renal Cell Carcinoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanzalintinib Fumarate in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanzalintinib Fumarate in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanzalintinib Fumarate in Metastatic Hepatocellular Carcinoma (HCC) Drug...